Nested Therapeutics Targets Mutations Hiding In Plain Sight
Newly launched with a $90m series A funding round, the company is taking the idea behind KRAS G12C inhibitors to another level.
You may also be interested in...
Deal Snapshot: The Nobel Prize winner co-founded biotech can extend its cash runway into 2025, while Roche gains access to an immunotherapy with potential to treat a wide range of cancers.
Lumakras data at ESMO in KRAS G12C-mutated lung cancer bested docetaxel on PFS, and largely on safety. OS was better for chemotherapy, but the trial was not powered for statistical significance on OS.
The company is reporting strong ORR, durability and PFS at ESMO in heavily pretreated colorectal cancer, an indication where Amgen’s Lumakras has struggled.